Macquarie Group ceases as substantial holder in Australian Clinical Labs

Macquarie Group Limited and its controlled bodies corporate, collectively "Macquarie Group Entities," have ceased to be a substantial holder in Australian Clinical Labs Limited (ACL). The change was effective on September 26, 2025.

The cessation involved various transactions, including on-market purchases and sales of shares by Macquarie Bank Limited (MBL), Macquarie Investment Management Australia Limited (MIMAL), and Macquarie Investment Management Global Limited (MIMGL). Notable transactions include MBL's stock sales of AUD 2.51248486 per security affecting -36,163 shares and AUD 2.50422126 per security affecting -90,236 shares, along with MIMGL's on-market purchases, such as 96,286 shares at AUD 2.52 per security. These movements highlight a strategic unwinding of Macquarie’s position in ACL.

The underlying Securities Lending Agreement between Macquarie Bank Limited and Vinva Investment Management Limited as a responsible entity indicates a transfer date of September 1, 2025. While the borrower held the right to vote on the securities, it could also return them early, providing flexibility in the arrangement that facilitated Macquarie's exit.